Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy.

MLA

Statland, Jeffrey M., et al. “Randomized Phase 2 Study of ACE‐083, a Muscle‐promoting Agent, in Facioscapulohumeral Muscular Dystrophy.” Muscle & Nerve, vol. 66, no. 1, July 2022, pp. 50–62. EBSCOhost, https://doi.org/10.1002/mus.27558.

APA

Statland, J. M., Campbell, C., Desai, U., Karam, C., Díaz, M. J., Guptill, J. T., Korngut, L., Genge, A., Tawil, R. N., Elman, L., Joyce, N. C., Wagner, K. R., Manousakis, G., Amato, A. A., Butterfield, R. J., Shieh, P. B., Wicklund, M., Gamez, J., Bodkin, C., & Pestronk, A. (2022). Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy. Muscle & Nerve, 66(1), 50–62. https://doi.org/10.1002/mus.27558

Chicago

Statland, Jeffrey M., Craig Campbell, Urvi Desai, Chafic Karam, Manera, Jordi Díaz, Jeffrey T. Guptill, Lawrence Korngut, et al. 2022. “Randomized Phase 2 Study of ACE‐083, a Muscle‐promoting Agent, in Facioscapulohumeral Muscular Dystrophy.” Muscle & Nerve 66 (1): 50–62. doi:10.1002/mus.27558.